U.S. Normal Saline for Parenteral Use Market Size, Share & COVID-19 Impact Analysis, By Type (Plastic Bottles and Glass Bottles), By Application (Intramuscular Injection and Intravenous Infusion), and Country Forecast, 2023-2030

The U.S. normal saline for parenteral use market size was valued at USD 1.19 billion in 2022 and is projected to grow at a CAGR of 7.4% during the forecast period.

Normal saline is the most commonly administered intravenous solution in clinical settings. The consumption of these solutions is increasing owing to the rising incidence of dehydration and hypovolemia associated disorders across the country. For instance,

• According to the data published by NCBI in 2022, about 75.0% of the American population is chronically dehydrated. Moreover, about 17% to 28% of older adults suffer from dehydration in the U.S.

Moreover, the rising number of patient visits and admissions across healthcare settings requiring intravenous administration of normal saline for the treatment of such chronic disorders boosts market growth.

• According to the data published by the Institute for Government in October 2023, the hospitals in NHS, completed 3.3 million admitted cases in 2022/23, an 11.0% increase respectively from 2021/22.

The COVID-19 pandemic profoundly impacted the market growth in 2020. A sharp decline in the number of surgeries, owing to low patient visits across healthcare settings and country lockdowns, negatively impacted the demand for normal saline.

U.S. Normal Saline for Parenteral Use Market Trends

High Demand for Normal Saline Across U.S. Healthcare Settings

The prevalence of chronic diseases among the U.S. population is high. Thus, the surge in prevalence has led to a rise in the number of inpatient admissions across clinical settings. Moreover, a rise in the incidence of hemodialysis and fluid replacement procedures as a treatment for chronic disorders across hospitals and clinics is evident across the country. Thus, the surge in disease prevalence and high demand for these solutions across healthcare settings has augmented the market growth in the U.S.

• According to data revealed by NCBI in 2021, normal saline is the most commonly used crystalloid solution, with over 200.0 million liters administered in the U.S. annually.

U.S. Normal Saline for Parenteral Use Market Growth Factors

Rising Emphasis on Capacity Expansion by Key Players to Augment Market Growth

The demand for intravenous solutions such as normal saline for parenteral use is high; however, the supply is limited across the nation. Thus, the market players are now focusing on strategic initiatives such as collaborations and new manufacturing centers to meet rising demand across clinical settings. Moreover, the rising adoption of advanced technologies to augment the production capacity by industry players will further propel the U.S. normal saline for parenteral use market growth.

• In August 2022, Assure Infusions, Inc. announced the construction of a manufacturing plant in Bartow, Florida. The center is fully automated with advanced robotics to make IV fluids that are in high demand in the U.S. healthcare system.

Request a Free sample to learn more about this report.

The total number of admissions in community U.S. hospitals was 32.0 million in 2022. The number of admissions across all U.S. hospitals in 2022 returned to the pre-pandemic level owing to an increase in the number of emergency department admissions in the U.S.

RESTRAINING FACTORS

Various Risks Associated with the Product to Limit Market Growth

The risks associated with intravenous solution preparation, such as fluid leakage and low fill volume, hampers the sterility of the isotonic solution, posing a risk for the patient of being exposed to a bacterial or fungal infection. Increasing incidence of improper packaging and distribution across clinical settings may also limit the use of normal saline in routine treatment procedures further hampering the market growth.

• For instance, according to the Food and Drug Administration (FDA) data in March 2022, B. Braun Medical Inc. voluntarily recalled five lots of 0.9% sodium chloride for injection USP 250ml in Excel at the hospital/user level within the U.S. The voluntary recall was initiated due to fluid leakage or low fill volume of the respective containers.

U.S. Normal Saline for Parenteral Use Market Segmentation Analysis

By Type Analysis

Based on type, the market is segmented into plastic bottles and glass bottles.

The plastic bottles segment held a larger share in 2022 and is expected to dominate the U.S. normal saline for parenteral use market during the forecast period. The larger share is owing to the high potential advantages of plastic bottles, such as lightweight, cost-effectiveness, and economical transportation as compared to glass bottles.

• According to data published by Origin Pharma Packaging in 2023, plastic-packed bottles for parenteral administration are highly durable, corrosion resistant, and possess flexibility as compared to glass bottles.

By Application Analysis

On the basis of application, the market is segmented into intramuscular injection and intravenous infusions.

The intravenous infusions segment held a larger share in 2022 owing to the high adoption of normal saline for parenteral use through intravenous injections among adults & children across hospitals and clinics. Moreover, increasing incidences of chronic conditions, such as diarrhea, vomiting, and hemorrhage, needing treatment by management of fluid resuscitation across health settings will augment the segmental growth during the forecast period. Moreover, rising focus of market players on extensive production owing to high demand further drives the segment growth.

• According to data published by Wolters Kluwer Health, Inc., in October 2022, an estimated 1.7 million adult sepsis cases are registered annually in the U.S.

List of Key U.S. Normal Saline for Parenteral Use Market Companies

In terms of the competitive landscape, the market depicts the presence of established and emerging IV solution manufacturers in the U.S. The established players, such as Baxter, B. Braun Melsungen AG, and ICU Medical Inc., dominated the U.S. market in 2022. The increasing focus of industry players on organic strategies, such as collaborations and partnerships with emerging manufacturers to expand their product portfolio, propels their revenue share in the market.

• In August 2020, ICU Medical Inc. announced that it has entered into a long-term agreement with Grifols, S.A., to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the U.S.

Some of the other companies with a considerable presence in the U.S. market include Grifols, S.A. Otsuka Pharmaceutical Co., Ltd., and others. The emerging players are now focusing on expanding their products’ geographical presence to boost their presence in the U.S. market. Such strategic moves are expected to enable companies to strengthen their U.S. normal saline for parenteral use market share during the forecast period.

An Infographic Representation of U.S. Normal Saline for Parenteral Use Market

View Full Infographic

To get information on various segments, share your queries with us

LIST OF KEY COMPANIES PROFILED:

• Baxter (U.S.)


• B. Braun Melsungen AG (Germany)


• ICU Medical, Inc. (U.S.)


• Fresenius Kabi AG (Germany)


• Otsuka Pharmaceutical Co., Ltd. (Japan)


• Assure Infusions, Inc. (U.S.)


• EuroLife Healthcare Pvt. Ltd (India)


• Grifols, S.A. (Spain)


• Pfizer Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• July 2021: Grifols, S.A., announced that it will establish an intravenous (IV) solutions production plant in Nigeria for Dozie and Dozie's Pharma Nig Ltd., a leading provider of healthcare products in the country and surrounding region.


• August 2020: ICU Medical, Inc., entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the U.S. Also, ICU Medical plans to distribute Grifols’ Dextrose IV solutions when those products have received regulatory clearance for sale in the U.S.


• July 2019: Eurolife Healthcare Pvt Ltd, a specialty pharmaceuticals company, acquired Isreal-based Teva's intravenous infusion (IV) unit in Hungary for the expansion of its operations in the Europe and U.S. market.

REPORT COVERAGE

The U.S. normal saline for parenteral use market research report includes an elaborative analysis of numerous factors affecting the U.S. market. Information on trends, drivers, opportunities, threats, and restraints of the market can further help stakeholders gain valuable insights into the market. The report also offers a detailed competitive landscape by presenting information on key players, market share by manufacturers, and their strategies.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation